XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Dynamic light scattering is the most widely used analytical method in nanoparticle characterization, and it is the method most likely to mislead you about the actual quality of your polymer nanoparticle drug product —
View details → Of all the CMC challenges in polymer nanoparticle drug product development, in vitro drug release testing is the most technically difficult, the most consequential for the regulatory submission and clinical development program, and the
View details →
FDA's classification of polymer nanoparticle drug products as "complex drug products" is not simply a regulatory label. It is a description of an analytical reality: the product's identity, purity, potency, and quality cannot be
View details → Polymer nanoparticle drug products do not have a dedicated regulatory pathway at FDA or EMA. They are regulated as drugs — with the same requirements that apply to any novel or improved drug product
View details → PLGA nanoparticles represent the established, well-precedented tier of polymer nanoparticle drug delivery. Beyond them lies a second tier — dendrimers and polymeric micelles — that offer properties unavailable from linear biodegradable polymer systems but
View details → Polymer nanoparticle drug delivery is not a mature field. The approved PLGA microsphere products represent one chapter in a technology that is actively generating the next chapters: stimuli-responsive systems that release drug in response
View details → Solid lipid nanoparticles are constructed from the same regulatory logic as PLGA nanoparticles — a matrix that encapsulates a drug, a size below 200 nm, and a surface coating that controls biodistribution. What the
View details → PLGA microspheres and PLGA nanoparticles are made from the same polymer, encapsulate the same drug candidates, and release their payload by the same hydrolytic degradation mechanism. The regulatory requirements that govern their CMC development,
View details → Iron oxide nanoparticles, gold nanoparticles, and mesoporous silica nanoparticles share a regulatory question that polymer and lipid nanoparticle CMC teams never have to answer: is the inorganic core the drug substance, or is it
View details → Iron oxide nanoparticle drug products present a CMC regulatory paradox: the iron is the drug — contrast enhancement or hyperthermia activity depends directly on iron content per dose and the magnetic properties of the
View details → Exosome and extracellular vesicle drug delivery programs sit in a regulatory space FDA has not fully mapped — between the CDER nanomedicine framework, where particle size, encapsulation efficiency, and release rate are the primary
View details → The regulatory frameworks that govern polymer nanoparticle drug products at FDA and EMA were developed largely in parallel, each authority issuing its own guidance and reflection papers without a formal multilateral harmonization process. A
View details →
The dissolution method you choose at IND is almost never the dissolution method that survives to NDA. The IND method is selected for analytical simplicity. The NDA method is selected for clinical relevance.
View details → The dissolution specification for an immediate release tablet is fundamentally a quality control tool — it confirms that the tablet disintegrates and releases the drug quickly. The dissolution specification for an extended release tablet
View details → HPMC hydrophilic matrix tablets are the most common controlled release platform in oral solid dosage form development — and the most commonly documented without the scientific argument that FDA chemistry reviewers need to evaluate
View details → For a 5 mg tablet where the API is 2.5% of the tablet weight, blend uniformity is not a process control — it is the single most consequential CQA in the manufacturing process. A
View details → A specification table in 3.2.P.5 is not a list of limits — it is a collection of regulatory arguments, each of which must be defended by data. When FDA chemistry reviewers ask "what is
View details → The 36-month shelf life on your oral tablet is a statistical prediction, not a measured fact — and the quality of that prediction depends entirely on whether the ICH Q1E linear regression model you
View details →